

AMENDMENT AND RESPONSE TO OFFICE ACTION  
U.S.S.N. 10/522,595

RECEIVED  
CENTRAL FAX CENTER

JUL 28 2008


**Amendment to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1 -46. (Cancelled)

47. (New) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



(I)

wherein

X and X' taken together form  $-C(R_5)=N-$ ;

Y is  $-C(R_5)-$  and taken together with the carbon atom bearing the phenyl group forms a double bond and R<sub>1</sub> is absent;

Y' is  $-N(R_5)-$ ;

Z forms a covalent single bond between X' and Y';

R<sub>2</sub> and R<sub>4</sub> are independently selected from hydrogen and C<sub>1-3</sub>alkyl;

R<sub>3</sub> is selected from C<sub>1-3</sub>alkyl and (A)<sub>m</sub>R<sub>12</sub>;

$-C(R_5)-$  is selected from  $-C(H)-$  and  $-C(C_{1-20}alkyl)-$ ;

$-N(R_5)-$  is selected from  $-N(H)-$  and  $-N(C_{2-20}alkyl)-$ ;

m is 0;

07/29/2008 PCHOMP 00000001 10552595

02 FC:2201


105.00 0P

AMENDMENT AND RESPONSE TO OFFICE ACTION  
U.S.S.N. 10/522,595

$R_{12}$  is selected from the group consisting of OH, SH,  $NH_2$ , halo,  $NO_2$ ,  $C(R_{17})_3$ ,  $OC(R_{17})_3$  and CN;

$R_{17}$  is independently selected from hydrogen and halogen; and  
wherein each alkyl may be optionally substituted.

48. (New) A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



wherein

X and X' taken together form  $-C(R_5)=N-$ ;

Y is  $-C(R_5)-$  and taken together with the carbon atom bearing the phenyl group forms a double bond and  $R_1$  is absent;

Y' is  $-N(R_5)-$ ;

Z forms a covalent single bond between X' and Y';

$R_2$  and  $R_4$  are independently selected from hydrogen and  $C_{1-3}$ alkyl;

$R_3$  is selected from  $C_{1-3}$ alkyl and  $(A)_m R_{12}$ ;

$-C(R_5)-$  is selected from  $-C(H)-$  and  $-C(C_{1-20}alkyl)-$ ;

$-N(R_5)-$  is selected from  $-N(alkyl)-$  wherein alkyl is selected from the group consisting of ethyl, n-propyl, *iso*-propyl, cyclopropyl, n-butyl, *sec*-butyl, *t*-butyl, cyclobutyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1-propylpropyl, 2-propylpropyl and cyclohexyl;

AMENDMENT AND RESPONSE TO OFFICE ACTION  
U.S.S.N. 10/522,595

m is 0;

R<sub>12</sub> is selected from the group consisting of OH, SH, NH<sub>2</sub>, halo, NO<sub>2</sub>, C(R<sub>17</sub>)<sub>3</sub>,  
OC(R<sub>17</sub>)<sub>3</sub> and CN;

R<sub>17</sub> is independently selected from hydrogen and halogen; and  
wherein each alkyl may be optionally substituted.

49. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein

Y is -CH-; and

X is -CH-.

50. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is OC(R<sub>17</sub>)<sub>3</sub>.

51. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is C<sub>1-3</sub>alkyl.

52. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R<sub>3</sub> is -CH<sub>3</sub> or -OCH<sub>3</sub>.

53. (New) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein N(R<sub>3</sub>)- is 3-methylbutyl.

54. (New) A compound wherein the compound is 4-(4-methoxyphenyl)-1-(3-methylbutyl)-1H-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

55. (New) A compound wherein the compound is 1-(3-methylbutyl)-4-(4-methylphenyl)-1H-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

56. (New) A pharmaceutical composition comprising a compound according to any one of claims 47, 48, 54 or 55, and a pharmaceutically acceptable carrier, diluent or excipient.

57. (New) The pharmaceutical composition according to claim 56 further comprising a glucocorticoid.